Efficacy of prothrombin complex concentrates for the emergency reversal of dabigatran-induced anticoagulation
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1364-8535
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Efficacy of prothrombin complex concentrates for the emergency reversal of dabigatran-induced anticoagulation ; volume:20 ; number:1 ; day:28 ; month:4 ; year:2016 ; pages:1-15 ; date:12.2016
Critical care ; 20, Heft 1 (28.4.2016), 1-15, 12.2016
- Urheber
- Beteiligte Personen und Organisationen
-
Aisenberg, James
Bernstein, Richard
Goldstein, Patrick
Huisman, Menno V.
Jamieson, Dara G.
Levy, Jerrold
Pollack, Charles V.
Spyropoulos, Alex C.
Steiner, Thorsten
Del Zoppo, Gregory J.
Eikelboom, John
SpringerLink (Online service)
- DOI
-
10.1186/s13054-016-1275-8
- URN
-
urn:nbn:de:1111-201604301551
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:50 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Grottke, Oliver
- Aisenberg, James
- Bernstein, Richard
- Goldstein, Patrick
- Huisman, Menno V.
- Jamieson, Dara G.
- Levy, Jerrold
- Pollack, Charles V.
- Spyropoulos, Alex C.
- Steiner, Thorsten
- Del Zoppo, Gregory J.
- Eikelboom, John
- SpringerLink (Online service)
Ähnliche Objekte (12)
Efficacy of prothrombin complex concentrates for the emergency reversal of dabigatran-induced anticoagulation
A French multicenter randomised trial comparing two dose-regimens of prothrombin complex concentrates in urgent anticoagulation reversal
Prothrombin complex concentrates and a specific antidote to dabigatran are effective ex-vivo in reversing the effects of dabigatran in an anticoagulation/liver trauma experimental model
Factor VIII Inhibitors: Therapeutic Response to Prothrombin Complex Concentrates
The effects between andexanet alpha and four-factor prothrombin complex concentrate on DOACs anticoagulation reversal
Successful intravenous thrombolysis for ischemic stroke after reversal of dabigatran anticoagulation with idarucizumab: a case report
Thrombogenic Characteristics of Activated and Standard Concentrates of Prothrombin Complex
Clinical review: Prothrombin complex concentrates - evaluation of safety and thrombogenicity
Recent Reduction in Thrombogenic Enzyme Content of Prothrombin Complex Concentrates
Reversal of rivaroxaban anticoagulant effect by prothrombin complex concentrates: which dose is sufficient to restore normal thrombin generation?
Idarucizumab: A novel antidote for reversal of dabigatran
Andexanet alpha versus four-factor prothrombin complex concentrate in DOACs anticoagulation reversal: an updated systematic review and meta-analysis
Efficacy of prothrombin complex concentrates for the emergency reversal of dabigatran-induced anticoagulation
A French multicenter randomised trial comparing two dose-regimens of prothrombin complex concentrates in urgent anticoagulation reversal
Prothrombin complex concentrates and a specific antidote to dabigatran are effective ex-vivo in reversing the effects of dabigatran in an anticoagulation/liver trauma experimental model
Factor VIII Inhibitors: Therapeutic Response to Prothrombin Complex Concentrates
The effects between andexanet alpha and four-factor prothrombin complex concentrate on DOACs anticoagulation reversal
Successful intravenous thrombolysis for ischemic stroke after reversal of dabigatran anticoagulation with idarucizumab: a case report
Thrombogenic Characteristics of Activated and Standard Concentrates of Prothrombin Complex
Clinical review: Prothrombin complex concentrates - evaluation of safety and thrombogenicity
Recent Reduction in Thrombogenic Enzyme Content of Prothrombin Complex Concentrates
Reversal of rivaroxaban anticoagulant effect by prothrombin complex concentrates: which dose is sufficient to restore normal thrombin generation?
Idarucizumab: A novel antidote for reversal of dabigatran
Andexanet alpha versus four-factor prothrombin complex concentrate in DOACs anticoagulation reversal: an updated systematic review and meta-analysis
Efficacy of prothrombin complex concentrates for the emergency reversal of dabigatran-induced anticoagulation
A French multicenter randomised trial comparing two dose-regimens of prothrombin complex concentrates in urgent anticoagulation reversal
Prothrombin complex concentrates and a specific antidote to dabigatran are effective ex-vivo in reversing the effects of dabigatran in an anticoagulation/liver trauma experimental model
Factor VIII Inhibitors: Therapeutic Response to Prothrombin Complex Concentrates
The effects between andexanet alpha and four-factor prothrombin complex concentrate on DOACs anticoagulation reversal
Successful intravenous thrombolysis for ischemic stroke after reversal of dabigatran anticoagulation with idarucizumab: a case report
Thrombogenic Characteristics of Activated and Standard Concentrates of Prothrombin Complex
Clinical review: Prothrombin complex concentrates - evaluation of safety and thrombogenicity
Recent Reduction in Thrombogenic Enzyme Content of Prothrombin Complex Concentrates
Reversal of rivaroxaban anticoagulant effect by prothrombin complex concentrates: which dose is sufficient to restore normal thrombin generation?
Idarucizumab: A novel antidote for reversal of dabigatran